Article Information
History
- October 20, 2020.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Ananda D. Lopes1,
- Nayane A.L. Galdino1,
- Amanda B. Figueiredo1,
- Rafael C. Brianese1,
- Katia L.P. Morais1,
- Marina De Brot1,
- Cynthia A.B.T1,
- Osório1,
- Andrea Teixeira-Carvalho2,
- Vinicius F. Calsavara1,
- Guilherme F.B. Evangelista1,
- Natalia S. Alves1,
- Fabiana B. Makdissi1,
- Solange M. Sanches1,
- Vladmir C. Cordeiro de Lima1,
- Dirce M. Carraro1,3 and
- Kenneth J. Gollob1,3,*
- 1A.C.Camargo Cancer Center, São Paulo, SP, Brazil
- 2Fundação Oswaldo Cruz (Fiocruz) - Instituto René Rachou, Belo Horizonte, MG, Brazil
- 3INCT- INCITO, São Paulo, SP, Brazil
- ↵*Corresponding Author:
Kenneth J. Gollob, Ph.D., Head Translational Immuno-oncology Group, International Research Center, A.C.Camargo Cancer Center, Sao Paulo, SP, Brazil, e-mail: kenneth.gollob{at}accamargo.org.br
Posted October 20, 2020.
Systemic immune mediators predict therapeutic response and tumor-infiltrating lymphocyte intensity in triple-negative breast cancer
